Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Dokumenty

T1500000

Tobramycin

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

Nebramycin Factor 6, O-[3-Amino-3-deoxy-α-D-glucopyranosyl-(1→6)]-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribohexopyranosyl-(1→4)]-2-deoxy-D-streptamine

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C18H37N5O9
Numer CAS:
32986-56-4
Masa cząsteczkowa:
467.51
Beilstein:
1357507
Numer MDL:
MFCD00077885
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329826678
NACRES:
NA.24

rodzina API

tobramycin

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

format

neat

temp. przechowywania

2-8°C

ciąg SMILES

NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O

InChI

1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1

Klucz InChI

NLVFBUXFDBBNBW-SNGYORCQSA-N

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Tobramycin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Działania biochem./fizjol.

Tobramycin is an aminoglycoside.
Mode of Action: Binds to 70S ribosomal subunit; inhibits translocation; elicits miscoding.
Spectrum of Activity: Gram negative bacteria. Not effective against Enterococci.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.
This page may contain text that has been machine translated.

Piktogramy

Health hazard
GHS08

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

H361f

Zwroty wskazujące środki ostrożności

P201 - P202 - P280 - P308 + P313 - P405 - P501

Klasyfikacja zagrożeń

Repr. 2

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Choose from one of the most recent versions:

Certyfikaty analizy (CoA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

David E Geller et al.
Journal of aerosol medicine and pulmonary drug delivery, 24(4), 175-182 (2011-03-15)
Abstract At present, the only approved inhaled antipseudomonal antibiotics for chronic pulmonary infections in patients with cystic fibrosis (CF) are nebulized solutions. However, prolonged administration and cleaning times, high administration frequency, and cumbersome delivery technologies with nebulizers add to the
Susan M Cheer et al.
Drugs, 63(22), 2501-2520 (2003-11-12)
Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis
David E Geller et al.
Chest, 122(1), 219-226 (2002-07-13)
To describe the pharmacokinetics and bioavailability of inhaled tobramycin (TOBI; Chiron Corporation; Seattle, WA), 300-mg dose, delivered by a nebulizer (PARI LC Plus; Pari Respiratory; Richmond, VA) and a compressor (Pulmo-Aide, model 5650D; DeVilbiss Health Care; Somerset, PA) in cystic
J G Penn-Barwell et al.
Bone & joint research, 3(6), 187-192 (2014-06-14)
The purpose of this study was to refine an accepted contaminated rat femur defect model to result in an infection rate of approximately 50%. This threshold will allow examination of treatments aimed at reducing infection in open fractures with less
V B Pai et al.
Pediatric pulmonology, 32(4), 314-327 (2001-09-25)
Aerosolized tobramycin has been extensively used in cystic fibrosis (CF) patients in order to directly deliver the antibiotic to the endobronchial site of infection, and decrease toxicity by limiting systemic absorption. Aerosolized tobramycin doses ranging from 80 mg twice or
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej